Chest X-rays should be ordered for patients who present to the ED with syncope.
Patients presenting to the emergency department with complaints of syncope should still undergo routine chest X-rays, according to a study published in the Western Journal of Emergency Medicine.
Researchers from Harvard Medical School, Beth Israel Deaconess Medical Center, in Boston, MA, sought to study the distribution of normal and abnormal chest radiographs in patients presenting with syncope, stratified by those who did or did not have an adverse event at 30 days.
The study included 575 patients, 39.7% male. The mean age for all patients was 57.2 years. The researchers assessed the frequency and findings for each CXR, as well as emergency department and hospital discharge diagnoses, and 30-day outcome.
A total of 403 (70.1%) CXRs were performed on the 575 subjects, and 116 (20.2%) of the patients had an adverse event after their syncope.
Fifteen of the 18 patients (83.4%) with an abnormal CXR had an adverse event. Eighty-one of the 385 patients (21.0%) with a normal CXR had an adverse event. Among those who had a CXR performed, an abnormal CXR was associated with increased odds of adverse event.
The researchers concluded that patients with syncope who have abnormal CXRs are more likely to experience an adverse event, though the majority of CXRs performed in the work up of syncope are normal.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.